Related Experiment Video
Updated: Jul 30, 2026
08:35
Production and Titering of Recombinant Adeno-associated Viral Vectors
Published on: November 27, 2011
61.9K
A packaging-regulated adenoviral vector for rAAV production
Dongbo Lu1, Rufei Li1, Qianqian Liang2
1State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, East China University of Science and Technology, Shanghai, 200237, China.
Biochemical and Biophysical Research Communications
|July 13, 2025
Summary
This study introduces a novel packaging-regulated adenovirus system for enhanced recombinant adeno-associated virus (rAAV) production. The system significantly boosts rAAV yield and infectivity, offering a scalable solution for gene therapy manufacturing.
Area of Science:
- Biotechnology
- Gene Therapy
- Virology
Background:
- Recombinant adeno-associated virus (rAAV) is crucial for gene therapy.
- Current rAAV production methods face challenges in scalability, yield, and quality.
Purpose of the Study:
- To develop a novel packaging-regulated adenoviral system for improved rAAV production.
- To enhance the scalability, yield, and quality of rAAV manufacturing.
Main Methods:
- Engineered an adenovirus by integrating a protocatechuic acid repressor (PcaR) binding site into the major late promoter (MLP) and inserting PcaR into the E1 region.
- Utilized protocatechuic acid (PCA) to regulate viral replication and gene expression.
- Delivered AAV Rep and Cap genes and the rAAV genome using the packaging-regulated adenoviral system.
Main Results:
- Achieved a 10-fold increase in genomic titer compared to helper-free plasmid methods.
- Observed significant enhancement in rAAV particle infectivity.
- Demonstrated that PCA, a green tea metabolite, offers a potentially safer alternative to antibiotics.
Conclusions:
- The packaging-regulated adenoviral system provides a high-yield, lower-contamination method for rAAV production.
- This strategy addresses critical challenges in rAAV manufacturing for gene therapy applications.
- The use of PCA offers a favorable safety profile for scalable rAAV production.
